CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10027|
|Strength||100mg/vial and 500mg/vial|
|Indication||Advanced Non-Squamous Non Small Cell Lung Cancer|
|Funding Request||For maintenance following first-line pemetrexed and cisplatin for advanced or metastatic Non Squamous -Non Small Cell Lung Cancer (NS-NSCLC)|
|Review Status||Notification to Implement Issued|
|Pre Noc Submission||No|
|NOC Date||May 9, 2013|
|Manufacturer||Eli Lilly Canada|
|Sponsor||Eli Lilly Canada|
|Submission Date||May 31, 2013|
|Submission Deemed Complete||June 13, 2013|
|Submission Type||New Indication|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||June 14, 2013|
|Check-point meeting||August 30, 2013|
|pERC Meeting||October 17, 2013|
|Initial Recommendation Issued||October 31, 2013|
|Feedback Deadline ‡||November 15, 2013|
|Final Recommendation Issued||November 19, 2013|
|Notification to Implement Issued||December 4, 2013|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.